These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32247373)

  • 1. Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience.
    Foltynie T; Athauda D
    Prog Brain Res; 2020; 252():493-523. PubMed ID: 32247373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.
    Glotfelty EJ; Olson L; Karlsson TE; Li Y; Greig NH
    Expert Opin Investig Drugs; 2020 Jun; 29(6):595-602. PubMed ID: 32412796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
    Kim DS; Choi HI; Wang Y; Luo Y; Hoffer BJ; Greig NH
    Cell Transplant; 2017 Sep; 26(9):1560-1571. PubMed ID: 29113464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.
    Athauda D; Foltynie T
    Neuropharmacology; 2018 Jul; 136(Pt B):260-270. PubMed ID: 28927992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.
    Victorino DB; Nejm M; Guimarães-Marques M; Scorza FA; Scorza CA
    Pharmaceut Med; 2021 Jan; 35(1):11-19. PubMed ID: 33409802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Exenatide a Treatment for Parkinson's Disease?
    Athauda D; Wyse R; Brundin P; Foltynie T
    J Parkinsons Dis; 2017; 7(3):451-458. PubMed ID: 28777758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic.
    Foltynie T; Aviles-Olmos I
    Alzheimers Dement; 2014 Feb; 10(1 Suppl):S38-46. PubMed ID: 24529524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.
    Athauda D; Foltynie T
    Drug Discov Today; 2016 May; 21(5):802-18. PubMed ID: 26851597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post hoc analysis of the Exenatide-PD trial-Factors that predict response.
    Athauda D; Maclagan K; Budnik N; Zampedri L; Hibbert S; Aviles-Olmos I; Chowdhury K; Skene SS; Limousin P; Foltynie T
    Eur J Neurosci; 2019 Feb; 49(3):410-421. PubMed ID: 30070753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes.
    Elbassuoni EA; Ahmed RF
    Neurochem Int; 2019 Dec; 131():104583. PubMed ID: 31654678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 and GIP receptor agonists in the treatment of Parkinson's disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies.
    Vaccari C; Grotto D; Pereira TDV; de Camargo JLV; Lopes LC
    PLoS One; 2021; 16(8):e0255726. PubMed ID: 34383800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists.
    Labandeira CM; Fraga-Bau A; Arias Ron D; Muñoz A; Alonso-Losada G; Koukoulis A; Romero-Lopez J; Rodriguez-Perez AI
    Front Neuroendocrinol; 2021 Jul; 62():100914. PubMed ID: 33845041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
    Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C
    Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
    Hölscher C
    Expert Opin Investig Drugs; 2020 Apr; 29(4):333-348. PubMed ID: 32175781
    [No Abstract]   [Full Text] [Related]  

  • 15. Parkinson's Disease, Diabetes and Cognitive Impairment.
    Ashraghi MR; Pagano G; Polychronis S; Niccolini F; Politis M
    Recent Pat Endocr Metab Immune Drug Discov; 2016; 10(1):11-21. PubMed ID: 27396477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitral cells and the glucagon-like peptide 1 receptor: The sweet smell of success?
    Bagnoli E; FitzGerald U
    Eur J Neurosci; 2019 Feb; 49(4):422-439. PubMed ID: 30120857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Old wines in new bottles: Repurposing opportunities for Parkinson's disease.
    Kakkar AK; Singh H; Medhi B
    Eur J Pharmacol; 2018 Jul; 830():115-127. PubMed ID: 29689247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
    Hölscher C
    Sheng Li Xue Bao; 2014 Oct; 66(5):497-510. PubMed ID: 25331995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
    Hölscher C
    Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T
    Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.